EAM Investors’s CytomX Therapeutics CTMX Stock Holding History

EAM Investors’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-565,113	Closed	-$2.66M	–	293
2026 Q1	$2.66M	Buy	565,113 +361,290	+177%	+$1.83M	0.31%	149
2025 Q4	$868K	Buy	+203,823	New	+$774K	0.1%	219
2025 Q3	–	Sell	-254,580	Closed	-$578K	–	280
2025 Q2	$578K	Buy	+254,580	New	+$410K	0.09%	205
2018 Q2	–	Sell	-42,990	Closed	-$1.22M	–	301
2018 Q1	$1.22M	Buy	+42,990	New	+$1.23M	0.2%	180
2016 Q2	–	Sell	-45,784	Closed	-$591K	–	313
2016 Q1	$591K	Buy	45,784 +10,928	+31%	+$152K	0.09%	293
2015 Q4	$727K	Buy	+34,856	New	+$552K	0.1%	299

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

EAM Investors's CTMX Position: Q2 2026 in Review

EAM Investors sold out of CytomX Therapeutics (CTMX) in Q2 2026, closing a stake of 565,113 shares — an estimated $2.66M sold.

EAM Investors first reported a position in CTMX in Q4 2015 and held it in 6 quarters. The position peaked at $2.66M in Q1 2026. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

EAM Investors reported no remaining CytomX Therapeutics position as of Q2 2026 after selling out during the quarter.
EAM Investors sold 565,113 CytomX Therapeutics shares in Q2 2026, an estimated $2.66M.
EAM Investors first reported a position in CytomX Therapeutics in Q4 2015 and held it in 6 quarters.
EAM Investors's CytomX Therapeutics position peaked at $2.66M in Q1 2026.
179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.